Penumbra Inc

2026-04-17 20:06:12

Penumbra's Board of Directors unanimously recommends shareholders vote FOR the proposed merger with Boston Scientific Corporation. A special meeting is scheduled for May 6, 2026, for shareholders to vote on the merger, and all necessary proxy materials have been distributed. Shareholders are urged to vote promptly, as failing to vote has the same effect as voting against the merger.

2026-04-16 08:39:51

Penumbra, Inc. (PEN) recently released 90-day results from its STORM-PE clinical trial, demonstrating that its computer-assisted vacuum thrombectomy (CAVT) technology, combined with anticoagulation, yielded superior functional outcomes and comparable safety for patients with intermediate-high risk pulmonary embolism compared to anticoagulation alone. These findings, particularly the improved six-minute walk distance, could significantly influence future treatment guidelines and boost the clinical adoption of Penumbra's CAVT technology, potentially reshaping the company's investment narrative by reinforcing its market position and growth prospects. However, investors should consider the potential for slower-than-anticipated adoption by hospitals, payers, or guideline committees, which could temper the commercial impact of these positive trial results.

2026-04-16 00:12:00

This article analyzes Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook while maintaining a positive long-term bias. It highlights resistance testing and presents three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strength, support, and resistance levels for various trading horizons.

2026-04-15 14:09:59

Penumbra, Inc. recently released 90-day results from its STORM-PE trial, indicating that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly improved functional outcomes and maintained comparable safety for patients with intermediate-high risk pulmonary embolism compared to anticoagulation alone. These Level 1 evidence findings, especially improved walking distance and functional recovery, could bolster the clinical adoption of Penumbra's CAVT technology and influence future treatment guidelines, thereby potentially reshaping the company's investment narrative. While the trial supports a near-term catalyst for CAVT adoption, investors should also consider the risk of slower-than-expected adoption by hospitals, payers, or guideline committees, despite strong revenue and earnings forecasts for Penumbra.

2026-04-15 10:30:00

Boston Scientific (NYSE: BSX) is set to acquire Penumbra (NYSE: PEN) for an estimated $14.9 billion, a strategic move to re-enter and dominate the stroke treatment market, which it exited previously. This acquisition is seen as one of the largest MedTech deals of the decade, signifying a significant consolidation trend in the healthcare sector. The deal is expected to create a comprehensive "Stroke Management Suite" leveraging Penumbra's advanced technologies and Boston Scientific's global distribution, though it faces integration challenges and regulatory scrutiny.

2026-04-14 20:38:46

This Simply Wall St analysis provides an overview of Penumbra (NYSE:PEN), a company specializing in medical devices for vascular and neurovascular diseases. The report highlights analyst consensus targeting a 9.1% undervaluation, a forecasted 17.2% annual earnings growth, and recent news including clinical trial results and executive stock sales. It also compares Penumbra to competitors and offers historical price performance data.